RESUMEN
BACKGROUND: Inflammatory bowel diseases are characterized by chronic intestinal inflammation that leads to severe destruction of the intestinal mucosa. Therefore, the understanding of their aetiology as well as the development of new medicines is an important step for the treatment of such diseases. Consequently, the development of Lactococcus lactis strains capable of delivering a eukaryotic expression vector encoding the interleukin 4 (IL-4) of Mus musculus would represent a new strategy for the elaboration of a more effective alternative therapy against Crohn's disease. RESULTS: The murine IL-4 ORF was cloned into the eukaryotic expression vector pValac::dts. The resulting plasmid-pValac::dts::IL-4-was transfected into CHO cells so that its functionality could be evaluated in vitro. With fluorescent confocal microscopy, flow cytometry and ELISA, it was observed that pValac::dts::IL-4-transfected cells produced IL-4, while non-transfected cells and cells transfected with the empty vector did not. Then, pValac::dts::IL-4 was inserted into L. lactis MG1363 FnBPA(+) in order to evaluate the therapeutic potential of the recombinant strain against TNBS-induced colitis. Intragastric administration of L. lactis MG1363 FnBPA(+) (pValac::dts::IL-4) was able to decrease the severity of colitis, with animals showing decreased levels of IL-12, IL-6 and MPO activity; and increased levels of IL-4 and IL-10. Finally, LP-isolated cells from mice administered TNBS were immunophenotyped so that the main IL-4 and IL-10 producers were identified. Mice administered the recombinant strain presented significantly higher percentages of F4/80(+)MHCII(+)Ly6C(-)IL-4(+), F4/80(+)MHCII(+)Ly6C(-)IL-10(+), F4/80(+)MHCII(+)Ly6C(-)CD206(+)CD124(+)IL-10(+) and CD4(+)Foxp3(+)IL10(+) cells compared to the other groups. CONCLUSIONS: This study shows that L. lactis MG1363 FnBPA(+) (pValac::dts::IL-4) is a good candidate to maintain the anti-inflammatory and proinflammatory balance in the gastrointestinal tract, increasing the levels of IL-10-secreting regulatory cells and, thus, demonstrating the effectiveness of this novel DNA delivery-based strategy.
Asunto(s)
Vectores Genéticos , Inflamación/terapia , Enfermedades Inflamatorias del Intestino/terapia , Interleucina-10/metabolismo , Interleucina-4/genética , Lactococcus lactis/genética , Animales , Células CHO , Cricetulus , Citocinas/inmunología , Citocinas/metabolismo , ADN/genética , Inflamación/inducido químicamente , Enfermedades Inflamatorias del Intestino/inmunología , Enfermedades Inflamatorias del Intestino/prevención & control , Interleucina-4/inmunología , Interleucina-4/uso terapéutico , Mucosa Intestinal/citología , Mucosa Intestinal/inmunología , Ratones , Membrana Mucosa/inmunología , Membrana Mucosa/ultraestructura , TransfecciónRESUMEN
Intestinal fibrosis associated with Crohn's disease (CD), which a common and serious complication of inflammatory bowel diseases. In this context, heat shock proteins (HSPs) might serve as an alternative treatment because these antigens play important roles in the regulation of effector T cells. We thus evaluated the anti-inflammatory and antifibrotic capacities of an invasive and Hsp65-producing strain-Lactococcus lactis NCDO2118 FnBPA+ (pXYCYT:Hsp65)-in chronic intestinal inflammation to assess its potential as an alternative therapeutic strategy against fibrotic CD. Experimental colitis was induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS) in BALB/c mice, and the mice were treated orally with L. lactis NCDO2118 FnBPA+ (pXYCYT:Hsp65) via intragastric gavage. The oral administration of this strain significantly attenuated the severity of inflammation and intestinal fibrosis in mice (p < 0.05). These results are mainly justified by reductions in the levels of the pro-fibrotic cytokines IL-13 and TGF-ß and increases in the concentration of the regulatory cytokine IL-10. The L. lactis NCDO2118 FnBPA+ (pXYCYT:Hsp65) strain contributed to reductions in the severity of inflammatory damage in chronic experimental CD, and these findings confirm the effectiveness of this new antifibrotic strategy based on the delivery of therapeutic proteins to inside cells of the host intestinal mucosa.
Asunto(s)
Proteínas Bacterianas/farmacología , Chaperonina 60/farmacología , Colitis/tratamiento farmacológico , Lactococcus lactis/genética , Animales , Proteínas Bacterianas/administración & dosificación , Chaperonina 60/administración & dosificación , Colitis/inducido químicamente , Colitis/patología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Femenino , Fibrosis/tratamiento farmacológico , Fibrosis/patología , Inmunoglobulina A/metabolismo , Ratones Endogámicos BALB C , Microorganismos Modificados Genéticamente , Ácido Trinitrobencenosulfónico/toxicidadRESUMEN
Objetivo: O estudo teve como objetivos comparar a viabilidade, cineticas de reativação e de colonização intestinal, e efeito imunomodulador de dois produtos probioticos comercializados no Brasil nas formas liofilizada e em suspensão aquosa, contendo Saccharomyces boulardii e Saccharomyces cerevisiae, respectivamente.Metodos : As leveduras Saccharomyces boulardii e Saccharomyces cerevisiae foram fornecidas nas suas formas comerciais liofilizada e em suspensão aquosa, respectivamente. Os dois produtos são comercializados no Brasil e depois de obtidos em farmácia, eles foram codificados como as letras A (lote No 1040276, fabricado em março 2004) e B (lote N° 040 30 33, também fabricado em março 2004), respectivamente. Os experimentos foram iniciados em junho de 2004, sendo que os prazos de validade indicados nos produtos eram de março de 2006 e setembro de 2005 para os produtos A e B, respectivamente. Resultados: somente o produto A apresentopu contagens iguais ou superiores ao indicado na bula, sendo que esses níveis se mantiveram estáveis ao longo dos seis meses. Em conclusão, o produto A apresentou melhores características de viabilidade, reativação, colonização e imunomodulação e esses fatos devem ser ligados, em parte, aos métodos diferentes de conservação dos produtos probióticos.